Filing Flows › Caris Life Sciences (CAI) › Guidance & outlook
Caris Life Sciences (CAI) guidance and outlook
Caris Life Sciences (CAI) raised its guidance on Nov 4, 2026: Revenue $1.0B–$1.1B for FY2026; Revenue +28% to +29% for FY2026. Caris Life Sciences' 10-Q filed Nov 4, 2026 makes 21 forward-looking statements.
Guidance and outlook
Latest guidance
| Metric | Period | Range | Change |
|---|---|---|---|
| Revenue | FY2026 | $1.0B–$1.1B | raised |
| Revenue | FY2026 | +28% to +29% | raised |
From the earnings release filed Nov 4, 2026 (8-K on EDGAR).
Forward-looking statements, 10-Q filed Nov 4, 2026
- Our historical results are not necessarily indicative of the results that may be expected for any period in the future.
- We believe this approach best positions us to provide actionable treatment pathways from targeted therapies to drive superior clinical outcomes for patients while also generating a rich dataset to power insights and innovation.
- platform also provide value to our biopharma partners, such as Moderna, AbbVie, Xencor, Merck KGaA and Genentech, through partnerships that aim to increase the probability of technical and regulatory success of their therapeutic pipelines.
- We believe our comprehensive approach to profiling will continue to drive demand for our genomic profiling capabilities, leading to further expansion of our clinico-genomic datasets, which provide additional valuable inputs to develop and enhance our solutions, with the ultimate goal of contributing to improved patient results.
- We believe we will be able to further leverage this process to continue meaningful innovation in precision oncology as well as other chronic disease states, including cardiology, neurology, and metabolic conditions.
- In addition, we expect that our ability to maintain and expand our
- sales, marketing, and distribution capabilities to support the increased adoption of our molecular profiling solutions will be a key factor in our success.
- As we continue to develop these relationships, we expect to support a growing number of projects and continue to have opportunities to offer our platform to such customers for development and research services.
- We plan to continue to invest in the enhancement of our molecular profiling solutions, the development of new solutions to achieve meaningful innovation in precision oncology and other disease states, and the expansion of our clinico-genomic datasets to drive breakthrough science.
- As the volumes of our current and new molecular profiling solutions continue to grow, we will need to simultaneously increase our capacity for sample intake and storage, enhance our customer service, improve our billing and general business processes, expand our internal quality assurance programs, incorporate new equipment, implement new technology systems and processes, expand laboratory capacity, and otherwise…
- Revenue is recorded at the amount that reflects the consideration to which we expect to be entitled from customers and third-party payers in exchange for providing such services.
- We expect cost of services to increase in absolute dollars as our revenue grows.
Caris Life Sciences' latest quarter
Caris Life Sciences, Q3 2026: revenue $275M (+27% year over year), operating margin 7.0%, net earnings $15.2M, operating cash flow −$22.2M. The chart follows the revenue to costs, profit and cash.
Questions
Did Caris Life Sciences raise or lower its guidance?
Caris Life Sciences (CAI) raised its guidance on Nov 4, 2026: Revenue $1.0B–$1.1B for FY2026; Revenue +28% to +29% for FY2026.
What does Caris Life Sciences expect?
Our historical results are not necessarily indicative of the results that may be expected for any period in the future. We believe this approach best positions us to provide actionable treatment pathways from targeted therapies to drive superior clinical outcomes for patients while also generating a rich dataset to power insights and innovation. platform also provide value to our biopharma partners, such as Moderna, AbbVie, Xencor, Merck KGaA and Genentech, through partnerships that aim to increase the probability of technical and regulatory success of their therapeutic pipelines.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.